Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Carasent, Audiocast, Q2'26

By Inderes7/10/2026, 6:00 AM
Carasent

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Daniel Öhman
00:02 - 10:56

Good morning and welcome to our presentation of the second quarter. My name is Daniel Öhman and with me is CFO Svein Martin Bjørnstad. Just a quick overview. First, at the center of any clinic or hospital is the EHR system. It is the same for Carasent, where we offer a number of EHR systems for different markets and needs. In addition, we offer a number of platform solutions that connect the caregivers with each other and other important players in the sector. And as you can see, we have highly recurring revenues of more than 90%, a 15% organic ARR growth and a 110% net revenue retention in the quarter. Looking at some of the highlights of the second quarter, I am very happy that we finally acquired InfoSolutions. That is something we have been working on for a number of years. It is an extremely important player in the sector and for our products, and I will talk more about that shortly. In the second quarter, we also had very strong sales in both new customers and add-on services as well. So, a bit later, our signed but not implemented revenue went from 4 million in Q1 to 6 million in Q2. And then most of those sales are Webcur. So almost all of the 4 million from last quarter have been implemented in this quarter. And the 6 million is to be implemented in the next. So those are almost all new sales in this quarter. So we have a really good and strong pace in the sales. I think that the organizational changes we have done are really working. I am very happy with that. For Germany, we have appointed a new CEO, a very experienced and entrepreneurial leader with a strong sales and marketing background, which I'm very happy about because we are gearing up for bringing Webcur to the market. So we really need to have the strongest team possible within sales and marketing. So I think that he will really help us move forward at a good pace and really modernize how we sell. So I am looking forward to him joining on the 1st of September, looking a bit at growth in the quarter. We have 29% growth in ARR. That is also thanks to InfoSolutions in the quarter. The organic growth is 15% and revenue growth in total is 11%. And that is the same as it was last quarter. I want to also note that for this quarter, we saw a bit lower revenue on the implementation and consulting side, mostly stemming from different Norwegian projects, both at Journal and at Webdoc. The profitability includes an adjusted EBITDA margin of 9% and an adjusted EBITDAC margin of 11%, which has been adjusted for the costs related to the cost-saving initiatives at InfoSolutions. So for almost all healthcare providers, it is absolutely key to be able to order tests for patients. So that includes blood tests, imaging, tissue samples, and so on. There are many different laboratories performing many different types of lab work. Many of you might know, just within blood, there are many different types of tests you can do. There are many different types of imaging you can do and different types of labs to which you want to send your samples and receive replies from. It is a quite complex network or a very complex network where InfoSolutions is really the key player and has an extremely strong position. So it has been a key part of both Webcur and Sweden for many years. It is an absolutely crucial part, actually. So we've been trying to buy it for a number of years, and it wasn't until now we could agree on a price. And I am very happy with it. They have this strong position that would really strengthen our offering in our Swedish systems and strengthen the entire Carasent group. Actually, what they have had is weak profitability for many years, and we have been working with the management team at InfoSolutions to really look over the cost structure and have agreed that what we can do is to make quite substantial savings on the headcounts. So we have lowered the personnel costs by 25%. It is already done and implemented. So all those that are leaving have signed and agreed. I believe that we will have a strong InfoSolutions going forward after this. We have also met with all the staff after the changes and feel that they understand why it was needed, and they also feel committed to us moving forward together and feel that we are in a strong position together. So that will really help InfoSolutions have a good position going forward and also have good profitability. We will also do a number of price increases. Those have already been communicated to quite many of the customers, and we believe InfoSolutions to be in a very strong position to implement those price increases, but that will take effect mostly from year-end. Looking at Medsum. So Medsum is our AI assistant. So what it does is listen to the conversation between the caregiver and the patient, and then automatically draft clinical notes so that the doctor, physiotherapist, or psychologist can review them to ensure accuracy and save significant time. It saves so much time. And that is what we hear from our customers. The ones using it really love it. They save a lot of time and can see extra patients or finish the day on time. It really should be an easy calculation for customers. Our customers see maybe 10 to 15 patients per day per caregiver, so per doctor or nurse and so on. And if it's a doctor, they have an average income of around 1,000 kronor per visit. And then the first day you take an extra patient, you have paid for Medsum for the entire month. And the other 19 work days of the month, you will make profits from using it. It also eliminates the most tedious part of the work. Having said that, I think we should be able to increase the pace of our sales quite significantly. It should be really easy. I think the things holding it back mostly is just that it is new. It is different. Caregivers are a bit afraid. Are we allowed to use this type of technology? Will the region say something about us using this technology and so on? So I think it is a bit of fear holding it back. We are trying to educate the customers. We also make sure that everything we do, of course, is compliant and accurate. We are really trying to build Carasent and Webdoc's standing in the community as a really compliant partner and a very knowledgeable partner. We are doing a number of seminars and so on to really show the compliance team we have, and we have invested a lot in our compliance team. It is quite a big compliance team. So, I feel that we're going to be able to push this forward. Many of the customers who have been won so far are from competing solutions, so it is still early adopters, but we are also getting some from brand new ones. We look forward to continuing to grow it. We can grow it with the present functionality. We have seen very limited churn so far. Given how differently you work with these technologies, I think it is significant that churn is very limited on such a different product compared to what they are used to using. We will add a lot of new functionality in the autumn. Then we will really, from every visit, also make a task list of everything you agree upon with the patient and then prefill all those things into the system. So you have ready solutions for everything you need to do after this. So all that administrative documentation that takes so much time away from healthcare, we can really help them save a lot of time. So I really look forward to releasing all that functionality in the autumn. It will all be there by the end of the autumn, because we are also rebuilding the UX of Webdoc to ensure it is a native solution within the system. But what we will also do in this regard in the autumn is obtain MDR certification. That is quite a heavy process to go through, but it seems like the authorities will demand that these solutions have the MDR certification, which will also make customers feel more at ease using this type of functionality. So it will cost us a couple of millions in the autumn, but it will be worth it. So that is something we aim to do during the beginning of the autumn. And we are really working hard to increase the pace of both sales and development in this sector because there is so much we can do for our customers. Looking forward to continuing our growth. I think we should. We are in a really strong position to continue to grow our customer base. Like our solutions, we have a really high pace in our development, making the difference between our systems and the competing systems more pronounced with every release. So our systems are getting better at a high pace. So I'm really happy about it. We continue to have strong cost control. So, we make sure to always know exactly what our costs are and we know what the cost will be next quarter. And we keep tight control of that. And every day we get a little bit better in everything we do. So that we can continue to grow without increasing costs very much. And we're launching Webcur in Germany, where we had the official launch on Midsummer Day in Munich. We really started showing it to the public. And then with Nils coming in to lead the team, taking this out to the market during the autumn, which I feel really happy about; with those words, I'm going to hand over to Svein Martin.

Svein Martin Bjørnstad
10:57 - 19:49

Thank you. Q2 was another strong quarter financially. No big surprises and another step in the right direction. So recurring revenues continue to grow strongly. And we also continue to convert the far majority of the revenue increases into profits. As you see here, contracted ARR is now 401 million and it grew 15% organically, with a net revenue retention of 110%, which shows that this strong underlying momentum continues with good upsell and very low churn. InfoSolutions added around 40 million of ARR, so total growth was 29% and profitability also continued to improve rapidly. We did have some extra costs that we adjusted for, which I will go through on the next page, but in general, it was a strong quarter, as mentioned. Looking at the P&L, the revenues came in at 97.7 million, 18% growth, where 11% was organic. So you see that, as mentioned, the recurring revenue growth was strong. The consulting side was a bit lower. But we do have a high activity now on the consulting side. And we had an improvement compared to Q1, which is positive, and the trend is going in the right direction. The gross margins were slightly lower than last year. It is partly because of InfoSolutions, which has a slightly lower gross margin than the rest of the group. On the cost side, you see that personnel expense and other opex increased a bit. It is mainly due to InfoSolutions and one-offs, with 300,000 related to transaction costs and 3.9 million related to restructuring and cost savings. A positive note on that is that the transaction cost was a lot lower than we had seen in previous acquisitions because we were able to do almost all the work internally this time. But in. This resulted in an EBITDAC improvement of around 8 million, and the margin increased from 3 to 11%. Looking at the ARR bridge, the growth remains balanced. We had a strong upsell, continued strong upsell. It is a mix. We continue to add new clinics for existing customers and new users. We also have a good upsell of new functionality. Medsum is starting to contribute to this, but it will also be a very important contributor in the coming years, we believe. If you look at the churn, it is 3%. However, the legacy products in Germany are churning quite a lot compared to the rest of the group. So that is around 1% of those 3%. So if you look at the churn in the Nordics, it is extremely low. Now it is 1.6%. So this has come down again after it was a bit elevated last year from bankruptcies, etc. But it shows that it was only temporary, which is very positive for us. New customers contributed with 5% growth. And then we also had InfoSolutions adding 42 million of ARR. InfoSolutions has also grown their ARR quite significantly over the last year, which is positive. The backlog is now 6 million compared to 12 million last year. You should bear in mind that last year we had a lot of these big contracts that had been in the backlog for many years. That has now been implemented. And the 6 million, as Daniel Öhman also mentioned, is mostly or only sales that we did in Q2. So, actually, that's a very strong quarter for us on the sales side. It was 4 million in Q1. So a strong development there as well. This slide, I show it every quarter because it is one of the best demonstrations of the leverage in the business. You see that orange line there on top is the revenue. It has grown around 120 million over the last couple of years. And then the dark blue part is the organic cash cost base. So opex, CapEx, and personnel costs are combined. And it has been essentially flat over the same period. And this. Bear in mind that this includes wage increases, inflation, etc. . So it basically means that we are able to take out cost because we also add cost, like we have done on the AI side for tokens and tools; we have added personnel in some areas, but we take out in other areas. So, the costs are essentially flat. And in this quarter, 83% of the revenue increase for the organic part, if we exclude M&A, dropped down to the profits, which is in line with what we aim for basically. But more than 100% of the gross profit increase actually dropped down to the bottom line. So costs were lower this quarter on an adjusted basis than last year. So in summary, we have good control of our costs and continue to become more efficient. Finally on the cash flow side, we had a very strong cash flow this quarter. And also for the first half of the year, you see here that free cash flow, including the CapEx investments, was 26% of revenue for the first half of 2026. So it was actually much stronger than even the EBITDAC. And this is because of the working capital effects. And I talked about this in Q4 and also in Q1. Q1 that there is some special effect in the working capital, for example, that one big customer paid in January instead of December. We also had a few high consulting revenues in December that were paid in January. So it is somewhat boosted, maybe around 15 million, but even adjusted for that, the working capital is very supportive for us because customers in general pay in advance for our products. Finally, on the capital allocation side, the InfoSolutions acquisition resulted in a net cash outflow. A net cash outflow of 92 million. And we also executed share buybacks of 40 million for the first half of the year. But our balance sheet remains solid with a cash position of 51 million at the end of the quarter and no debt. So with that, we can stop there and open up for questions.

Operator
20:04 - 20:21

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Elvin Roleder from Carnegie. Please go ahead.

Elvin Roleder
20:23 - 21:18

Good morning, Daniel and Svein Martin. I hope you can hear me. A couple of questions from my side, perhaps beginning a bit on InfoSolutions. It is encouraging to see the swift actions you are able to take. I just have a couple of questions. If you can get a bit more granular on where you're taking out costs within the organization and provide a clarification. I think in the report you said 25% of the cost base. But you mentioned personnel costs here in the presentation; which one is the most correct to look at? And is there any kind of potential impact on top line from what you are taking out? Or is it purely more admin or back-office-based costs you are removing from the organization?

Daniel Öhman
21:22 - 23:15

Yeah. Good morning. Uh thank you. Yes, first of all, I am sorry about the unclear reasoning in our presentation. So 25% of staff costs were taken out. So it is roughly 10 million, right? Yeah. Yeah. Yeah. So it is staff cost we are taking out. And it will have no effect on the top line. So I would say that InfoSolutions had a really great time during COVID because all those tests went through their platform. So you can see that from the history of the company. They were really, really boosted during that period of time. I think that added a lot of staff, and they never really got out of that cost situation. So, the staff had been making all this money and they never really took care of that cost situation afterwards. They have been doing things during those years. They have been in no hurry to do things. I think they have been quite fine with it, and they have been growing their business a little bit again after the Covid effect disappeared. But we wanted to see more. We needed to see more swift action. That is why we moved in like this. My experience is also that we did a similar thing in the beginning of Carasent when I joined. It is quite good to make sure that you take all costs in one go, and then you build from there instead of doing it a little bit now and then, because then everyone knows this is the team that will do it together going forward, and they can feel reasonably safe in that. So I think that is why it is important to do it swiftly and do it in one go. And also, to make sure that you're honest with the staff from day one. And that is what we were aiming for. Did that make sense?

Elvin Roleder
23:16 - 23:35

Yeah. Yes, it makes perfect sense. But then just maybe to clarify, because I guess most of the company's costs are personnel-related to begin with. Regarding personnel-related costs to begin with, what kind of a reasonable net savings on the total OpEx base are you targeting? What is a reasonable net saving on the total OpEx base? If it was 25% of personnel costs that were removed.

Daniel Öhman
23:36 - 23:39

Yes, it is 10 million in cost savings per year.

Elvin Roleder
23:40 - 24:43

Okay. Okay, great. Thank you. And then moving on to MDR for Medsum. I mean, I guess previously my impression from you guys has been that you kind of want to avoid MDR, considering the cumbersome process that it is, but I guess now this is kind of a hedging towards the regulators if they were to become more strict in this, but I guess it also unlocks more features for you guys to be able to roll out to clinics. Given that it will now be, or probably will be, certified in a couple of months, are there any specific features that the customers, doctors, and clinics have been requesting that you have previously been unable to roll out due to this MDR hindrance, which you will be able to roll out now? Or is it more purely a hedging effect from a regulatory standpoint, or how should we view that?

Daniel Öhman
24:44 - 27:14

So yes, I understand. It is correct that we have been trying to avoid MDR historically, I would say. I think most companies are a bit afraid of MDR. It is quite a big process. But the last couple of years we've done so much with our ISO certifications and other regulations hitting our industry. So we have become quite good at it. And we have a strong compliance team. So we feel quite confident that this will not be a major undertaking for us. It will cost a bit of money. We need to conduct some studies and so on. So, we are much less afraid of it, so to speak, today than we were a couple of years ago. It also seems that the regulation has matured in how it is implemented. So it is also easier to understand what we need to do. There are no significant new things we can do thanks to MDR, but we can make our customers feel more safe. It's mostly a black-box market. You are the ones responsible in Sweden who are saying that, okay, we will start saying that this is MDR. Over time, we might have been able to get away with not doing it, but it is important that our customers feel safe in using this technology. So I think it makes sense to do it from that perspective. There are some minor things we can do. So for example, today when we do the documentation after the meeting, we propose an entire medical record. Except for the diagnosis. So I don't think that's a major problem for most of our customers. Certainly, diagnosis is really simple. They have very many routine patients, so they do not need support. And it is also part of the role they like the most. But doing MDR, we will start proposing diagnoses too. But it's not the major advantage. I see it, it is more about keeping customers safe. But it is also the case that Sweden seems to have a different opinion than the rest of Europe. So I think this is more of a Swedish perspective regarding MDR. I don't think it will happen in Norway, for example, but there will be MDR, of course, also in Norway on this functionality. So, that is fine. And we will use it in marketing as much as we can. Sweden in general seems to take a bit more strict view on these things than the rest of Europe, I would say.

Elvin Roleder
27:16 - 28:08

Okay. Very clear. Perhaps a last question before I will leave the room for others to ask. Regarding Medsum. Of course. It is positive to see that the user base is steadily increasing month over month. And I guess it is still, of course, very early days and that a lot of the users now are, as you mentioned, previous users of a different, similar kind of solution. But regarding the interest overall from Medsum, have you seen any clear patterns on types of clinics that are interested in the product? Or are you seeing any disparities between smaller versus bigger clinics that can indicate where the majority of the adoption will come from in a three-year period, or any trends you have picked up since launching the product?

Daniel Öhman
28:09 - 30:08

I would say it's mostly semi-small clinics and it's mostly stayed on a user basis. For example, one can have two people who like this AI stuff and they get it, but not the rest of them. It is still seldom that we see a clinic buying it for everyone. Yeah. So it is still kind of the case that individuals really like the AI features. And maybe he has been using a bit of ChatGPT and now he can do it in the right way. So that is good. I think it's a matter of time. And this is Swedish healthcare, especially Swedish healthcare, that is very careful. You have to remember that doctors and nurses are trained to do right and to make no errors. They also know there are a lot of regulations in that area, and they know they are personally responsible for what they do and what they write in the medical notes, as their own license is at stake. The personal license as a doctor or as a nurse. So it is a very careful group of people. They are accustomed to working in very old systems. Everyone is trained in the public sector where they typically use these systems. So, it will not be rapid growth. I think we should be able to increase the pace. I think that is my personal view. I think it is such a good time saver for them. So they should really all use it. And we are going to do everything we can to push it. But I think it is most likely that we will see steady, somewhat slow growth because it is a very careful industry that is heavily regulated. Everyone is trained not to make mistakes. They are personally responsible. So it will not be a boom. It will be a steady growth. I think where they pick it up person by person.

Elvin Roleder
30:09 - 30:16

Yeah. Okay. Great. Thank you for taking my questions. I'll get back in the queue and leave the room for others.

Daniel Öhman
30:16 - 30:17

Thanks, everyone.

Operator
30:20 - 30:24

The next question comes from Frederik Nielsen from Redeye. Please go ahead.

Frederik Nielsen
30:25 - 30:52

Thank you. Good morning, Daniel and San Martin. Just a few more questions on InfoSolutions. And regarding the numbers you present here for ARR. For InfoSolutions. In the presentation, it seems to have increased from 34 million last year to 42 million. If you look at net ARR, is that the correct interpretation?

Svein Martin Bjørnstad
30:53 - 31:22

Yes, that is correct. But towards the end of last year, they did acquire a small customer portfolio and that was included. So that is part of it; it is like 4 or 5 million of the growth. So the rest of their growth is organic. So the organic growth is taking them from like 38 to 42, basically.

Frederik Nielsen
31:25 - 31:33

Okay, great. That is clear, but still quite reasonable organic growth. Then what's driving that growth?

Svein Martin Bjørnstad
31:34 - 32:09

I would say it is mainly from new customers being added. It is like they grow a lot together with the systems, for example, together with Webcur. And they have also added some additional regions that started using their system and some functionality that has also driven a bit of the growth, but it is a mix, while the main driver has been adding new customers for them.

Frederik Nielsen
32:11 - 32:27

Okay, great. And as you touched upon some of the customers or your competitors, what has the reaction been so far regarding the purchase and also the announced price increases?

Daniel Öhman
32:29 - 34:14

So it's been a bit mixed. I think many of them understand the price increase. Many of them say that. Yeah. I mean, as InfoSolutions, you haven't raised prices for like ten years. So it makes sense that you raise some prices. So I think many of them are quite fine. We have implemented a price change that has created a little more frustration among some of them. And that is that historically, I feel that InfoSolutions kind of supported the new systems into the market by saying that, oh wait, you can just get it almost for free, and then you just pay as you add more users. But it is quite a significant cost to implement a new EHR system into it. So from now on, you really have to pay for it. So that is a change that some of the smaller systems have not really liked. But otherwise, I think that most of them have understood it. And also some of the smaller customers have understood that. Yeah. It makes sense not to. We should not subsidize small systems entering the market. So I think that has been quite okay. It is important for us to keep those customers, or most of them at least, and they are important partners to us also when it comes to Medsum and HP. So we have been talking to some of the larger customers about that. We have good collaborations, both when it comes to the EHR and from before, and we will continue to have a good collaboration. We are being transparent upfront about our plans, and we follow through on our commitments so you can trust us. And I think they know that from the past couple of years. So I think that it will work. Okay.

Frederik Nielsen
34:16 - 34:25

Okay, I see. Could you give us any indication about what kind of price increases on average we are talking about?

Daniel Öhman
34:28 - 35:23

Yeah. It is very different between different customers. And we will treat our own system and other large competitors the same. It is just that I will not substitute small ones. Then we have a lot of regions and public labs where we are not allowed to increase prices as much as we think we should, even though they haven't done it historically; they haven't always used the KPIs that are in the agreements with regions. However, in some cases, we are allowed to increase it. Also, historically for the regions, in some cases we cannot. And in some cases with some regions, they are currently in the tender process, so you cannot increase prices at all. So it is not included in the contract, but I think we will be able to do an average of around 20% maybe.

Svein Martin Bjørnstad
35:25 - 35:32

It is worth mentioning that that is on an ARR basis. So it is not like for the total revenue base.

Frederik Nielsen
35:34 - 35:49

Great. Thanks. And just one last question from me regarding Germany. You mentioned modern marketing and sales. Could you give us some examples of what kind of initiatives those are?

Daniel Öhman
35:51 - 37:29

Yeah. You have to bear in mind that sales and marketing is different in Germany than in Sweden. So, we do sell a lot at fairs, for example. We don't do that in Sweden. So you have the physiotherapists and doctors going to fairs looking at different systems and actually signing contracts at the fair. So I was at the fair in Munich on Midsummer's Day where we launched Webcur. And you have customers coming there looking at the system and signing contracts at the fair. So that's quite different. And we have to bear that in mind in everything we do. So that's why it's important to drive it locally. And our sales in Germany are very much cold visits, physical visits to customers still. The salespeople are doing a great job being able to do that and are actually closing those sales, which we saw working well in Germany. We tried it a little bit in Sweden, but it did not work at all. But still, I think we can do a lot to make sure that salespeople are working warmer leads. We have historically done very little marketing to create leads in Germany. So that is something we really look forward to doing more. We also want to grow the sales team. We have a good sales team, but we want to grow it and we want to provide them with better working conditions. And we also want to give them better systems to work in so they really know which customers to target and which are the most likely to buy and so on. So I think there is quite a lot we can do with the structures and processes around it to strengthen our sales. And we have that already. And that is what I am looking forward to doing.

Frederik Nielsen
37:32 - 37:35

Great. That is all for me. Thank you very much.

Svein Martin Bjørnstad
37:35 - 37:37

Thank you. Thanks.

Operator
37:37 - 37:50

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Victor Lindström from SpareBank 1 Markets. Please go ahead.

Victor Lindström
37:53 - 38:13

Hi guys. I hope you can can hear me. Yeah. Yeah. Perfect. Thank you. So I have two more technical questions. So if you look at the gross margin here in the quarter, that was a bit weaker compared to Q4. What is driving this, or what is the factor behind this?

Svein Martin Bjørnstad
38:15 - 38:42

It is partly because of adding InfoSolutions, which has a slightly lower gross margin than the rest of the group. And also partly because we had quite high transaction revenues compared to the previous quarters. And those typically drive costs as well. So those are the two main reasons.

Victor Lindström
38:45 - 39:06

Perfect. Thanks. And if you look at the CapEx spending, that was down 1 million both sequentially and versus last year. Now that you have InfoSolutions on board, should we expect CapEx spending to increase once again? Or do you expect the current levels to be sustainable?

Svein Martin Bjørnstad
39:08 - 39:45

Yeah, I would say we don't expect any increase from InfoSolutions. We probably won't capitalize any development there, as we look at it now at least. But the CapEx has been quite stable around plus or minus 10 million a quarter for quite some time now. Our main focus is on the total cash cost base and not what we capitalize or not. But I would say that's a reasonable level to expect going forward as well.

Victor Lindström
39:47 - 39:50

Right. Perfect. Thank you very much from me.

Svein Martin Bjørnstad
39:51 - 39:52

Thank you.

Operator
39:54 - 40:01

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Svein Martin Bjørnstad
40:02 - 40:16

Okay, we have gotten a few questions in the chat as well. First one from Richard Dearlove. The churn in the German business seems quite high. Are these churning customers not interested in Webcur?

Daniel Öhman
40:17 - 42:22

So what we are churning in Germany is from their product, Data, which is an on-prem solution from the 90s. That has been developed since then, of course, but it is basically the case that for doctors, it will take a long time before Webcur can really replace Datan. So our aim is to first replace the data product. There are many names here, but it is a physiotherapy software that they already had in the data element acquired. So we are first meeting those customers because those are the easiest to convert, and also because there is a regulation change in Germany during the end of next year requiring more physiotherapists to use this type of software. Many still use pen and paper. So that is why we are focused on that first and then going to doctors. So we really need to keep doctors satisfied with that for many years to come with the product Data. So what we are doing is acknowledging that we will have high churn in that product. So I can start by saying that, but what we are doing to achieve lower churn is to really do a lot of development and also increase the pace there. I think we've done some good things when it comes to how we work with development in the product, setting more structures and learning from what we do in other countries. So I feel that we have a better pace in development there now on that product without adding staff. And we also have better stability in what we release in that product. So, roughly a year ago, we had a lot of problems with our releases in Dator. And that seems to be solved now. So the last couple of quarters, the release has been stable and that should bring the churn down. But we will have higher churn in that product and other products until we can replace it. But it will take a couple of years.

Svein Martin Bjørnstad
42:27 - 42:42

Okay. Next one from Niklas. What is the status of potential larger deals? More relevant to Medsum. Do you see any activity with regards to procurement within the next 12 months?

Daniel Öhman
42:43 - 43:48

Yeah. So we have really good discussions with customers. So, not really of the size of that. It might not be large enough to release, but I would expect us to close some deals with Medsum on a similar basis. In the next couple of quarters. So I think we have good traction. Webcur has really taken a lot of our efforts and it is very important to have them as a very satisfied customer. It contributes to our ARR. They will be a good customer for many years. And they are also a good reference for us. So it is important for us to keep them really happy. And that has taken a lot of effort and cost over the last couple of years a little bit more. That will now ease. We will sign some new good customers in the coming quarters, maybe not of the Webcur size, but quite big ones.

Svein Martin Bjørnstad
43:51 - 44:04

Next one from Yannick. A couple of questions. Could you elaborate on the situation in Germany a bit more, please? How will the release of the new software look from a timeline point of view?

Daniel Öhman
44:04 - 46:43

Yeah. So, it still takes a lot of time to build software for the medical community that really fits the customer. I think the team is doing a good job. We have a really high patient development level like I have never had before, but it is still an elaborate process to really meet customers, having the first ones in there, fixing what they feel should be changed and moving on and so on. The first paying customer we brought online in the last quarter had I think 12 major things they wanted changed by the team owning that part. And we have done almost all of it, but the next one will have new things. So it takes time. And then the functionality of Webcur is much slower than, for example, what we have in Webdock. So it still takes a lot of time to build good solutions and maybe not to write the code as much as it used to, but the entire process. But we see ourselves meeting the needs of private therapists of different sizes and structures during the autumn, probably by the end of the year. Also the ones treating public patients, by that I mean the public German insurance, which most therapists do. So it will be important to meet that functionality need. It is quite complex, but we will be there during the autumn, and then we will start meeting doctors during next year, but then it will be the easiest doctors. And moving on from that, a system like Webdoc that has been building functionality since the 90s. It takes time, but in my view, we need to do some more with the product to really be there. The sales team is not really pushing it full-on yet. We cannot do that yet. We are getting there and that is what we are gearing up for to really push it. I hope that we will be able to really push it by Q4 this year. But for now, the most important thing is to make sure that the customers and different types of customers at the level which we now want to support are really happy with all parts of the system, and that takes some time to iron out. I wish we had come further in it, but it still takes a lot of time.

Svein Martin Bjørnstad
46:45 - 46:56

Next one. Could you talk about your product vision with regards to Webdoc as your flagship product? MDR, Medsum, etc. How do you think about this from a strategic point of view?

Daniel Öhman
46:57 - 50:13

Yeah. I am really happy with what we are doing in Webdock. We have a really strong position with almost no churn with any new customers. Having, for example, big customers wanting to roll out more and more clinics. We have Stockholm moving over from Cosmic to Take Care. Take care. So everyone in Stockholm needs to change systems no matter what. And that is usually a hard thing for us to convince anyone of. And if you compare Cosmic and Webdoc for this type of customer, it is not a competition. I think it's almost a bit better. Yeah. So maybe I shouldn't say that, but we have a really good product for this type of customer, and in two years' time, our product will be even better than it is today. So we have a really high pace. I think many of the systems that we are competing with do not have a development pace close to ours. We are rebuilding the entire UX to, first of all, take care of things that people have historically not liked about the system, also make it look and feel more modern, and make AI a native part of it. So it will be quite changed by the end of this year. We have already started rolling out those UX changes. But step by step, we really need to educate the customer on each step. I think most people recognize from their normal work that you don't really like when software changes, but it is important to change, otherwise it gets old. So we are pushing that through. It will result in many calls to our support center, but we can really make the system much more efficient. Use. Our aim is to save time for our users so they can treat more patients. That is always the aim. And if you look at what takes the most time for them, it's all administration, and LLM models are really good at administration. So our aim is to do as much of the administration as we legally and possibly can do in a safe way for our customers. And that is a lot, I think. I look forward to rolling out that functionality during the autumn. And then we'll continue, of course, to add more functionality after that, and the pace that we can have now in development lets us do so much more. So if you look at Webdoc or one of the really big solutions, we have a lot of functionality. If you compare it to the number of developers we have, that is how it looks in this sector. So we can really do a lot to improve the products, even if Webdoc is a great product compared to others. There is still so much I wish we could do, and we have a long list of things we want to do, and we tick them off at a higher and higher pace to really save time for our customers. I look forward to continuing to do that.

Svein Martin Bjørnstad
50:15 - 50:29

Great. Thanks. One from Erasmus. Uh, good morning. Going into Germany. Are you targeting the whole market, or will you focus on certain regions to build a strong presence and get some word of mouth to help drive growth?

Daniel Öhman
50:30 - 52:13

So, we're not talking. Word of mouth is important. So we will probably have that if we win one customer. Otherwise, knowing them will be easy to sell to. So I think that our efforts need to support that, but mostly what we are aiming for are certain types of users rather than certain regions. So, in the beginning, it is therapists and therapists working with private pay insurance. That accounts for about 30% of the insurance market, focusing solely on that segment. Many customers have a mix. So that really limits the number of potential customers we can have at this point in time. It will increase quite substantially once we can also serve public insurance. So by the end of this year, hopefully a bit sooner. And then we can aim for those. We have, for example, a really good customer called the Fisher Family. They have a significant online presence, a strong team, and they utilize digital marketing strategies to reach their audience. That provides us with significant visibility. So in their different channels, they have the Swedish team coming there and talking to them. I think that is a great customer, the type of customer we want to have at this moment that really can spread the word. I mean, we are doing everything we can to keep them happy. I think it is mostly certain types of customers rather than certain regions.

Svein Martin Bjørnstad
52:15 - 52:43

Okay. The final question here is in Swedish, but I will translate it. How does the market look in Stockholm? Are you seeing any changes with potential customers? There has been a lot of discussion in the media about Cosmic. How does this affect you? Do you see any risk that the tender process they won will be redone?

Daniel Öhman
52:44 - 56:54

If you look at the signed implementations for the next quarter or from this 5.45 million, which is mostly Webdoc, a large part of that is clinics in Stockholm. From all these tenders now, I am not talking about tenders on software, but tenders on care. So that meant that some clinics closed and they are opening new ones. And many of the new ones opening are using Webdoc. So I think that's a really good signal. We still have that. It's the big change like restrictions. So that is what is important now, as they know Webdoc. So they know it is a better software, so they will use it in a new clinic. Many of the ones leaving the public sector are opening their own clinics. They know the care environment. So that is the challenge we have. So we need to get the word of mouth out there more. It is quite good to grow with the big chains because doctors go there, gain experience, and open their own clinics. So that really strengthens our knowledge about Webdoc. The discussions on Cosmic, I think, go in two ways. It, and I should also say, as I guess most of you know, that is a media narrative. There are people who are happy with Cosmic and people who are not happy with Cosmic. So, a change of systems is never easy. People are generally not happy with that. And so in the healthcare sector, that is the challenge we always have, that we need to be so good that it is an easy choice to change. The ones that have been the least happy with Cosmic are the ones that are left. Take Care is a quite user-friendly software, and other regions left for software that isn't very user-friendly; Take Care is actually a really user-friendly software, but it lacks a lot of functionality that we provide, so the ones that are the least happy are the ones leaving. Take care. So that is what Stockholm will also do. And that will be in a couple of years. And by then, it will be much better than today. It is more difficult for a system like Cosmic to move forward when you have all these regions that impose so many demands. When it comes to functionality, then you cannot really work with the workflow and the user experience the same way. I have no clue if there is a risk that they will redo the tender for Stockholm on Cosmic. I think there has to be much more media about it before that happens. It is a very big decision to make. I mean, look at Stockholm. It took many years of problems before they actually stopped implementing Millennium. So I think that's unlikely. If it were to happen, it would probably be negative for us because that means all the caregivers would be affected. Okay. There will be something else coming possibly in the future at some point in time. And it's always an easier choice not to change the EHR system and just wait for something that might happen. So many customers look for excuses not to change. I would say so. I believe it is best if nothing changes in that timeframe. But it is not the major factor. Most of it. Most of it comes down to us delivering results ourselves. Make sure that we are well known in Stockholm. Continue winning customers from Cosmic. It is in our hands to really make sure that we have the best option out there for our type of customer. So, Cosmic and others are focusing on the regions. They do a pretty good job at that. And that is a really difficult customer to have. But it's almost impossible, I would say, to be the best EHR system for an entire region and for our type of customer. So, we actually work towards different markets.

Svein Martin Bjørnstad
56:55 - 57:17

And also, TakeCare is not really investing in or developing their system forward. So if it would be many more years before they change that system, the gap towards Webcur would increase over time as well. Yeah, that was the final question.

Daniel Öhman
57:18 - 57:28

Okay, then thank you all for calling in this morning. Yes. Let us know if you have any follow-up questions. We are always available, and I wish you all a good summer when you get there.

Svein Martin Bjørnstad
57:28 - 57:29

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…